fullerene paclitaxel conjugate synthesized slow release drug aerosol liposome delivery paclitaxel lung cancer therapy conjugate designed release paclitaxel enzymatic hydrolysis subsequently half life release min bovine plasma liposome formulation conjugate prepared dilauroylphosphatidylcholine dlpc ic virtually identical ic paclitaxel dlpc formulation human epithelial lung carcinoma cells clinically relevant kinetics hydrolysis cytotoxicity tissue culture conjugate holds promise enhanced therapeutic efficacy paclitaxel vivo 